JP Patent

JP6782855B2 — 選択性ブルトン型チロシンキナーゼ阻害剤及びその使用

Assigned to 杭州和正医薬有限公司 · Expires 2020-11-11 · 6y expired

What this patent protects

Patent listed against Imbruvica.

Drugs covered by this patent

Patent Metadata

Patent number
JP6782855B2
Jurisdiction
JP
Classification
—
Expires
2020-11-11
Drug substance claim
No
Drug product claim
No
Assignee
杭州和正医薬有限公司
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.